194 related articles for article (PubMed ID: 25488073)
41. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
42. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
43. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
44. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
Nghiemphu PL; Liu W; Lee Y; Than T; Graham C; Lai A; Green RM; Pope WB; Liau LM; Mischel PS; Nelson SF; Elashoff R; Cloughesy TF
Neurology; 2009 Apr; 72(14):1217-22. PubMed ID: 19349600
[TBL] [Abstract][Full Text] [Related]
45. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.
Lu-Emerson C; Norden AD; Drappatz J; Quant EC; Beroukhim R; Ciampa AS; Doherty LM; Lafrankie DC; Ruland S; Wen PY
J Neurooncol; 2011 Aug; 104(1):287-91. PubMed ID: 21153679
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
47. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
48. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Lalezari S; Zaw T; Motevalibashinaeini K; Mischel PS; Pope WB
J Neurooncol; 2012 Jan; 106(1):111-9. PubMed ID: 21706273
[TBL] [Abstract][Full Text] [Related]
49. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
[TBL] [Abstract][Full Text] [Related]
50. Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model.
Ramezani S; Vousooghi N; Ramezani Kapourchali F; Joghataei MT
Apoptosis; 2017 Aug; 22(8):1025-1034. PubMed ID: 28616662
[TBL] [Abstract][Full Text] [Related]
51. Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
[TBL] [Abstract][Full Text] [Related]
52. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Chamberlain MC
Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
[TBL] [Abstract][Full Text] [Related]
53. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
54. The VEGF gene polymorphism in glioblastoma may be a new prognostic marker of overall survival.
Djan I; Lucic S; Bjelan M; Vuckovic N; Vucinic N; Morganti AG; Djan M; Lucic M
J BUON; 2019; 24(6):2475-2482. PubMed ID: 31983122
[TBL] [Abstract][Full Text] [Related]
55. Association between single nucleotide polymorphisms of
Zhong W; Guo X; He Y; Yasen M; Adilai M; Abudubari H; Abudukadier A; Alifu X
J Obstet Gynaecol; 2022 Jul; 42(5):1347-1351. PubMed ID: 34693869
[TBL] [Abstract][Full Text] [Related]
56. Associations of
Vasconcelos VCA; Lourenço GJ; Brito ABC; Vasconcelos VL; Maldaun MVC; Tedeschi H; Marie SKN; Shinjo SMO; Lima CSP
Tumour Biol; 2019 Sep; 41(9):1010428319872092. PubMed ID: 31486713
[TBL] [Abstract][Full Text] [Related]
57. Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis.
Madrid-Paredes A; Casado-Combreras MÁ; Pérez-Ramírez C; Segura-Pérez AM; Chamorro-Santos C; Vergara-Alcalde E; Sánchez-Pozo A; Calleja-Hernández MÁ; Cañadas-Garre M
Pathol Res Pract; 2020 Apr; 216(4):152860. PubMed ID: 32127237
[TBL] [Abstract][Full Text] [Related]
58. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.
García-Romero N; Palacín-Aliana I; Madurga R; Carrión-Navarro J; Esteban-Rubio S; Jiménez B; Collazo A; Pérez-Rodríguez F; Ortiz de Mendivil A; Fernández-Carballal C; García-Duque S; Diamantopoulos-Fernández J; Belda-Iniesta C; Prat-Acín R; Sánchez-Gómez P; Calvo E; Ayuso-Sacido A
BMC Med; 2020 Jun; 18(1):142. PubMed ID: 32564774
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of bevacizumab in glioblastomas.
De Fazio S; Russo E; Ammendola M; Donato Di Paola E; De Sarro G
Curr Med Chem; 2012; 19(7):972-81. PubMed ID: 22214463
[TBL] [Abstract][Full Text] [Related]
60. Anti-VEGF Therapy with Bevacizumab--limited cardiovascular toxicity.
Yu J; Cao XF; Zheng Y; Zhao RC; Yan LQ; Zhao L; Wang JW
Asian Pac J Cancer Prev; 2014; 15(24):10769-72. PubMed ID: 25605173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
